SCHEMBL5539498

SCHEMBL5539498

[CH2]CCCCC(=O)c1ccccc1OC(F)(F)F

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 1/20 0.45
HDAC1 Q13547 1/20 0.45
F2R P25116 1/20 0.43
FFAR4 Q5NUL3 2/20 0.42
KCNK3 O14649 4/20 0.41
KCNK9 Q9NPC2 4/20 0.41
CYP11B1 P15538 1/20 0.40
CYP11B2 P19099 1/20 0.40
RXRA P19793 1/20 0.39
RXRB P28702 1/20 0.39
RXRG P48443 1/20 0.39
HSD11B1 P28845 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
OPRM1 P35372 1/20 0.37
FFAR1 O14842 1/20 0.37
HCN1 O60741 1/20 0.37
HCRTR1 O43613 1/20 0.37
HCRTR2 O43614 1/20 0.37
MGLL Q99685 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5547816 0.99 HDAC8 (0.47) HDAC8HDAC1F2RFFAR4KCNK3
SCHEMBL5544348 0.95 F2R (0.43) HDAC8HDAC1F2RFFAR4KCNK3
SCHEMBL2094649 0.89 F2R (0.45) HDAC8HDAC1F2RFFAR4KCNK3
SCHEMBL2097392 0.83 KCNK3 (0.47) F2RFFAR4KCNK3KCNK9CYP11B1
SCHEMBL28134724 0.82 HDAC8 (0.45) HDAC8HDAC1F2RFFAR4KCNK3
SCHEMBL28134725 0.78 POLB (0.43) HDAC8HDAC1F2RFFAR4KCNK3
SCHEMBL5540580 0.77 CTNNB1 (0.57) HDAC1F2R
SCHEMBL29585736 0.76 PTPN1 (0.46) F2RFFAR4KCNK3KCNK9CYP11B1
SCHEMBL29268934 0.76 KCNK3 (0.46) F2RFFAR4KCNK3KCNK9CYP11B1
SCHEMBL2098762 0.76 PTPN1 (0.46) F2RFFAR4KCNK3KCNK9CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 HDAC8 993/4885HDAC1 322/4885F2R 4611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.